Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in hyperkalaemia compared with selective aldosterone antagonist (low certainty).

1 finding from 1 review

Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
RR 0.89 [0.45, 1.77]
1 study · 1023 participants
Low

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

Death · proteinuric chronic kidney disease

Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in death compared with selective aldosterone antagonist (low certainty).

1 finding from 1 review

Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
RR 0.7 [0.31, 1.55]
1 study · 1055 participants
Low

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

Cardiovascular events · proteinuric chronic kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

Doubling serum creatinine · proteinuric chronic kidney disease

Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in doubling serum creatinine compared with selective aldosterone antagonist (low certainty).

1 finding from 1 review

Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
RR 0.8 [0.03, 19.51]
1 study · 1055 participants
Low

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

AKI · proteinuric chronic kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

Proteinuria · proteinuric chronic kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

eGFR · proteinuric chronic kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Aldosterone antagonists vs placebo or usual care

Doubling serum creatinine · proteinuric CKD

Aldosterone antagonists showed no clear difference in doubling serum creatinine compared with placebo or standard care (low certainty).

1 finding from 1 review

Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
RR 1.3 [0.69, 2.44]
2 studies · 875 participants
Low